Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach


Halter, J., Schüpbach, W.M.M., Casali, C., Elhasid, R., Fay, K., Hammans, S., Illa, I., Kappeler, L., Krähenbühl, S., Lehmann, T., Mandel, H., Marti, R., Mattle, H., Orchard, K., Savage, D., Sue, C. M., Valcarcel, D., Gratwohl, A. and Hirano, M. (2011) Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplantation, 46, (3), 330-337. (doi:10.1038/bmt.2010.100).

Download

[img] PDF
Restricted to Repository staff only

Download (320Kb) | Request a copy

Description/Abstract

Allogeneic hematopoietic SCT (HSCT) has been proposed as a treatment for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). HSCT has been performed in nine patients using different protocols with varying success. Based on this preliminary experience, participants of the first consensus conference propose a common approach to allogeneic HSCT in MNGIE. Standardization of the transplant protocol and the clinical and biochemical assessments will allow evaluation of the safety and efficacy of HSCT as well as optimization of therapy for patients with MNGIE.

Item Type: Article
ISSNs: 0268-3369 (print)
0268-3369 (electronic)
Related URLs:
Subjects: R Medicine > RC Internal medicine
Divisions: Faculty of Medicine > Cancer Sciences
ePrint ID: 341438
Date Deposited: 25 Jul 2012 10:48
Last Modified: 27 Mar 2014 20:24
URI: http://eprints.soton.ac.uk/id/eprint/341438

Actions (login required)

View Item View Item